SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFrontier Ip Regulatory News (FIPP)

Share Price Information for Frontier Ip (FIPP)

Share Price is delayed by 15 minutes
Get Live Data
17.00    0.00 (0.00%)
Bid:
16.00
Ask:
18.00
Spread: 2.00 (12.50%)
Market Cap: £12.86m
FIPP Live PriceLast checked at - London Stock Exchange

Intraday Frontier Ip Share Chart

Trading update

12 Jan 2022 07:00

RNS Number : 1353Y
Frontier IP Group plc
12 January 2022
 

The information contained within this announcement is deemed by the Group to constitute inside information as stipulated under the Regulation 11 of the Market Abuse (Amendment) (EU Exit) Regulations 2019/310 ("MAR"). With the publication of this announcement via a Regulatory Information Service, this inside information is now considered to be in the public domain.

 

RNS

AIM: FIPP

12 January 2022

 

 

 

Frontier IP Group plc

("Frontier IP" or the "Group")

 

Trading update

 

Frontier IP (AIM: FIPP), a specialist in commercialising intellectual property, is today providing a trading update ahead of publication of its interim results for the six months to 31 December 2021 ("H1 2022") which are expected to be released in March 2022. The Group has enjoyed a strong first half to the financial year in particular due to the IPO on the Nasdaq Global Select Market of portfolio company Exscientia plc ("Exscientia") during the period.

 

Exscientia reported a strong set of quarterly results post admission and, on 7 January 2022, announced a strategic research collaboration with Sanofi that will entitle Exscientia to an upfront cash payment of $100 million with the potential for $5.2 billion in total milestones plus tiered royalties. The uplift in book value of this holding as at 31 December 2021 is expected to make a significant contribution to the performance of the Group in H1 2022.

Further to the release of the Group's full year results in October 2021, Frontier IP has now commenced a programme to realise part of its shareholding in Exscientia. As at the date of this announcement a small portion has been sold in January 2022 and the Group will provide a further update at the appropriate time.

The Group's portfolio as a whole has continued to show strong commercial and technical progress and a number of the companies are reaching key inflection points. During the period The Vaccine Group announced encouraging data on the development of its next generation COVID-19 vaccine, Camgraphic completed a fundraising and management was strengthened at Pulsiv. This momentum is continuing into 2022 and yesterday we were pleased to note Celerum launching its Truck Logistics System at a time when supply chain challenges are high on the priority list for many businesses.

 

While it is clear there are many challenges facing markets and industry, we anticipate reporting a set of results for H1 2022 ahead of management expectations and continuing to build on progress in the balance of the financial year. We remain confident on the Group's prospects for the remainder of the financial year and beyond.

 

ENQUIRIES

 

Frontier IP Group Plc

Neil Crabb, Chief Executive

Andrew Johnson, Communications & Investor Relations

Company website: www.frontierip.co.uk

 

T: 020 3968 7815 neil@frontierip.co.uk

M: 07464 546 025

Allenby Capital Limited (Nominated Adviser)

Nick Athanas / George Payne

 

T: 0203 328 5656

Singer Capital Markets (Broker)

Sandy Fraser / Harry Gooden / George Tzimas

T: 0207 496 3000

 

 

ABOUT FRONTIER IP

Frontier IP unites science and commerce by identifying strong intellectual property and accelerating its development through a range of commercialisation services. A critical part of the Group's work is involving relevant industry partners at an early stage of development to ensure technology meets real world demands and needs.

The Group looks to build and grow a portfolio of equity stakes and licence income by taking an active involvement in spin-out companies, including support for fund raising and collaboration with relevant industry partners at an early stage of development.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTUAORRURUAAUR
Date   Source Headline
7th Dec 201711:50 amRNSResult of AGM
8th Nov 20177:00 amRNSPosting of Annual Report and Notice of AGM
30th Oct 20175:15 pmRNSHolding(s) in Company
30th Oct 201712:00 pmRNSPortfolio News PulsiV Granted Two US Patents
24th Oct 20177:00 amRNSFinal Results
9th Oct 20177:00 amRNSExscientia Wins Emerging Biotech Company Award
28th Sep 20177:00 amRNSExscientia announces investment from Evotec
25th Sep 20171:12 pmRNSHolding(s) in Company
20th Sep 20177:00 amRNSAlusid extends range at London Design Festival
7th Sep 20177:00 amRNSCSI launches novel sensor system at IFA Berlin
8th Aug 20177:00 amRNSNew Portfolio Company - The Vaccine Group
28th Jul 20173:26 pmRNSHolding(s) in Company
20th Jul 20177:00 amRNSPortfolio News- Nandi Proteins Limited Fundraising
11th Jul 20174:38 pmRNSHolding(s) in Company
5th Jul 20177:00 amRNSNew Portfolio Company - MolEndoTech
3rd Jul 20177:00 amRNSExscientia announces major GSK collaboration
11th May 20177:00 amRNSGrant of Options
9th May 201712:05 pmRNSRoyal Society of Chemistry Nominations
9th May 201711:25 amRNSExscientia announces major Sanofi collaboration
30th Mar 20177:00 amRNSHalf-Year Results for the 6 Months to 31 Dec 2016
24th Mar 20174:33 pmRNSHolding(s) in Company
23rd Mar 20173:27 pmRNSHolding(s) in Company
23rd Mar 20173:26 pmRNSHolding(s) in Company
23rd Mar 20173:25 pmRNSHolding(s) in Company
17th Mar 201712:10 pmRNSPlacing to raise £3 million
8th Feb 20177:00 amRNSChange of Adviser
23rd Dec 201611:45 amRNSResult of AGM
7th Dec 20167:00 amRNSNew Portfolio Company - Tarsis Technology Limited
28th Nov 20167:00 amRNSPosting of Annual Report and Notice of AGM
21st Nov 20167:00 amRNSAudited final results for year ended 30 June 2016
4th Nov 201611:00 amRNSALUSID Wins Prestigious IChemE Award
14th Sep 201611:50 amRNSAgreement with FCT, Universidade NOVA de Lisboa
5th Sep 20167:00 amRNSNandi Proteins Participant in £1m Funding Award
27th Apr 20167:00 amRNSex scientia Limited - Partnership with Evotec AG
11th Apr 20163:31 pmRNSHolding(s) in Company
7th Apr 20167:05 amRNSHolding(s) in Company
7th Apr 20167:00 amRNSGrant of Options
31st Mar 20168:30 amRNSHolding(s) in Company
30th Mar 20169:00 amRNSHolding(s) in Company
24th Mar 20167:00 amRNSEquity Placing raising £1.0M & Total Voting Rights
9th Mar 20167:00 amRNSHalf-year results for the 6 months to 31 Dec 2015
7th Mar 20167:00 amRNSNandi Proteins Ltd: Further Successful Fundraising
8th Feb 20167:00 amRNSAgreement with first Portuguese University
21st Dec 201512:16 pmRNSResult of AGM
7th Dec 20157:00 amRNSAlusid wins prestigious Product of the Year award
1st Dec 20157:00 amRNSHolding(s) in Company
30th Nov 20154:20 pmRNSHolding(s) in Company
26th Nov 20157:00 amRNSPosting of Annual Report and Notice of AGM
19th Nov 20157:00 amRNSPreliminary results for year ended 30 June 2015
27th Oct 20157:00 amRNSPortfolio Company Fundraising - PulsiV Solar Ltd

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.